Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q8LD | ISIN: BMG210A71016 | Ticker-Symbol: MX6A
Frankfurt
08.10.25 | 09:59
0,905 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
GRAND PHARMACEUTICAL GROUP LTD Chart 1 Jahr
5-Tage-Chart
GRAND PHARMACEUTICAL GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8950,96513:54
0,8950,96013:54

Aktuelle News zur GRAND PHARMACEUTICAL GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
24.09.GRAND PHARMA (00512): INTERIM REPORT 2025-
24.09.GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
24.09.GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
23.09.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE3
GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln
08.09.Sirtex Medical Inc.: Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres253Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading...
► Artikel lesen
08.09.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ...2
27.08.GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTION-
19.08.GRAND PHARMA (00512): 2025 INTERIM RESULTS ANNOUNCEMENT-
05.08.GRAND PHARMA (00512): DATE OF BOARD MEETING1
28.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP2
22.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE ...1
17.07.GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT TO CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT1
17.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST NASAL SPRAY PRODUCT OF THE GROUP FOR THE TREATMENT OF DRY EYE DISEASE, OC-01, ACHIEVES ...2
07.07.SIR-Spheres® Y-90 Harz-Mikrosphären von Sirtex Medical erhalten FDA-Zulassung für die Behandlung des inoperablen Leberzellkarzinoms379Woburn, Massachusetts (ots/PRNewswire) - Erweiterte Indikation macht SIR-Spheres® zur ersten und einzigen Radioembolisationstherapie in den USA, die sowohl zur Behandlung des inoperablen Leberzellkarzinoms...
► Artikel lesen
07.07.Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma252Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN...
► Artikel lesen
07.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: A NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ...2
04.06.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE OPHTHALMIC DRUG CBT-001 COMPLETES THE ENROLLMENT OF ALL PATIENTS IN THE INTERNATIONAL ...3
12.05.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE III STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDX COMPLETES PATIENT ENROLLMENT ...2
07.05.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN INTERNATIONAL MULTICENTER PHASE III ...-
07.05.Grand Pharmaceutical Group Limited: The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China426The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1